Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs During Chronic Kidney Disease

Overview

Journal Toxins (Basel)

Publisher MDPI

Specialty Toxicology

Date 2019 Apr 10

PMID 30959953

Citations 6

Authors

Tacy Santana Machado

Claire Cerini

Stephane Burtey

Affiliations

Soon will be listed here.

Abstract

Chronic kidney disease (CKD) is a major public health problem, since 300,000,000 people in the world display a glomerular filtration rate (GFR) below 60 mL/min/1.73m². Patients with CKD have high rates of complications and comorbidities. Thus, they require the prescription of numerous medications, making the management of patients very complex. The prescription of numerous drugs associated with an altered renal- and non-renal clearance makes dose adjustment challenging in these patients, with frequent drug-related adverse events. However, the mechanisms involved in this abnormal drug clearance during CKD are not still well identified. We propose here that the transcription factor, aryl hydrocarbon receptor, which is the cellular receptor for indolic uremic toxins, could worsen the metabolism and the excretion of drugs in CKD patients.

Citing Articles

Unveiling the role of sex in the metabolism of indoxyl sulfate and apixaban.

Pina-Beltran B, Dimitrov D, McKay N, Giot M, Zdrahal Z, Potesil D Sci Rep. 2025; 15(1):6075.

PMID: 39972038 PMC: 11839926. DOI: 10.1038/s41598-025-90405-5.

The role of murine M1 macrophages from different sources in unilateral ureteral obstruction.

Cui X, Hu Y, Zhang G, Zhao L, Ye T, Zhang Q Cent Eur J Immunol. 2023; 48(2):81-91.

PMID: 37692024 PMC: 10485685. DOI: 10.5114/ceji.2023.129975.

Association of vascular endothelial growth factor (VEGF) protein levels and gene polymorphism with the risk of chronic kidney disease.

Liu Y, Hong K, Weng W, Huang S, Zhou T Libyan J Med. 2022; 18(1):2156675.

PMID: 36484457 PMC: 9744219. DOI: 10.1080/19932820.2022.2156675.

Host-microbiome interactions: Gut-Liver axis and its connection with other organs.

Anand S, Mande S NPJ Biofilms Microbiomes. 2022; 8(1):89.

PMID: 36319663 PMC: 9626460. DOI: 10.1038/s41522-022-00352-6.

Drugs Commonly Applied to Kidney Patients May Compromise Renal Tubular Uremic Toxins Excretion.

Mihaila S, Faria J, Stefens M, Stamatialis D, Verhaar M, Gerritsen K Toxins (Basel). 2020; 12(6).

PMID: 32545617 PMC: 7354492. DOI: 10.3390/toxins12060391.

References

Matsushita K, van der Velde M, Astor B, Woodward M, Levey A, de Jong P . Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375(9731):2073-81. PMC: 3993088. DOI: 10.1016/S0140-6736(10)60674-5. View

Kaminski T, Pawlak K, Karbowska M, Mysliwiec M, Pawlak D . Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease. BMC Nephrol. 2017; 18(1):35. PMC: 5267373. DOI: 10.1186/s12882-017-0457-1. View

Gao C, Ji S, Dong W, Qi Y, Song W, Cui D . Indolic uremic solutes enhance procoagulant activity of red blood cells through phosphatidylserine exposure and microparticle release. Toxins (Basel). 2015; 7(11):4390-403. PMC: 4663509. DOI: 10.3390/toxins7114390. View

Schroeder J, Dinatale B, Murray I, Flaveny C, Liu Q, Laurenzana E . The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry. 2009; 49(2):393-400. PMC: 2805781. DOI: 10.1021/bi901786x. View

Naud J, Michaud J, Leblond F, Lefrancois S, Bonnardeaux A, Pichette V . Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos. 2007; 36(1):124-8. DOI: 10.1124/dmd.107.018192. View

Nolin T, Appiah K, Kendrick S, Le P, McMonagle E, Himmelfarb J . Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol. 2006; 17(9):2363-7. DOI: 10.1681/ASN.2006060610. View

Mason N . Polypharmacy and medication-related complications in the chronic kidney disease patient. Curr Opin Nephrol Hypertens. 2011; 20(5):492-7. DOI: 10.1097/MNH.0b013e328349c261. View

Santana Machado T, Poitevin S, Paul P, McKay N, Jourde-Chiche N, Legris T . Indoxyl Sulfate Upregulates Liver P-Glycoprotein Expression and Activity through Aryl Hydrocarbon Receptor Signaling. J Am Soc Nephrol. 2017; 29(3):906-918. PMC: 5827590. DOI: 10.1681/ASN.2017030361. View

Erichsen T, Ehmer U, Kalthoff S, Lankisch T, Muller T, Munzel P . Genetic variability of aryl hydrocarbon receptor (AhR)-mediated regulation of the human UDP glucuronosyltransferase (UGT) 1A4 gene. Toxicol Appl Pharmacol. 2008; 230(2):252-60. DOI: 10.1016/j.taap.2008.02.020. View

10.

Rhee E, Souza A, Farrell L, Pollak M, Lewis G, Steele D . Metabolite profiling identifies markers of uremia. J Am Soc Nephrol. 2010; 21(6):1041-1051. PMC: 2900954. DOI: 10.1681/ASN.2009111132. View

11.

Kot M, Daniel W . Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat. Pharmacol Rep. 2009; 60(6):789-97. View

12.

Zhou J, Zhang J, Xie W . Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyl-transferases. Curr Drug Metab. 2005; 6(4):289-98. DOI: 10.2174/1389200054633853. View

13.

Parajuli B, Georgiadis T, Fishel M, Hurley T . Development of selective inhibitors for human aldehyde dehydrogenase 3A1 (ALDH3A1) for the enhancement of cyclophosphamide cytotoxicity. Chembiochem. 2014; 15(5):701-12. PMC: 4043872. DOI: 10.1002/cbic.201300625. View

14.

Mimura J, Fujii-Kuriyama Y . Functional role of AhR in the expression of toxic effects by TCDD. Biochim Biophys Acta. 2003; 1619(3):263-8. DOI: 10.1016/s0304-4165(02)00485-3. View

15.

Ikuta T, Eguchi H, Tachibana T, Yoneda Y, Kawajiri K . Nuclear localization and export signals of the human aryl hydrocarbon receptor. J Biol Chem. 1998; 273(5):2895-904. DOI: 10.1074/jbc.273.5.2895. View

16.

Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P . Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003; 63(5):1934-43. DOI: 10.1046/j.1523-1755.2003.00924.x. View

17.

Fujii H, Nishijima F, Goto S, Sugano M, Yamato H, Kitazawa R . Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant. 2009; 24(7):2089-95. DOI: 10.1093/ndt/gfp007. View

18.

London G, Guerin A, Marchais S, Metivier F, Pannier B, Adda H . Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003; 18(9):1731-40. DOI: 10.1093/ndt/gfg414. View

19.

Hubbard T, Murray I, Perdew G . Indole and Tryptophan Metabolism: Endogenous and Dietary Routes to Ah Receptor Activation. Drug Metab Dispos. 2015; 43(10):1522-35. PMC: 4576673. DOI: 10.1124/dmd.115.064246. View

20.

Nolin T, Frye R, Le P, Sadr H, Naud J, Leblond F . ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol. 2009; 20(10):2269-76. PMC: 2754095. DOI: 10.1681/ASN.2009010082. View